• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Tectonic Therapeutic Inc.

    8/27/24 4:01:49 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECX alert in real time by email
    S-8 POS 1 d887797ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on August 27, 2024

    Registration No. 333-281690

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    to

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Tectonic Therapeutic, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   83-0710585

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    490 Arsenal Way

    Suite 210

    Watertown, MA

      02472
    (Address of Principal Executive Offices)   (Zip Code)

    2019 Equity Incentive Plan

    2024 Equity Incentive Plan

    2024 Employee Stock Purchase Plan

    (Full titles of the plans)

    Daniel Lochner

    Chief Financial Officer

    490 Arsenal Way

    Suite 210

    Watertown, MA 02472

    (339) 666-3320

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Marc A. Recht

    Courtney T. Thorne

    Katherine Denby

    Cooley LLP

    500 Boylston Street, 14th Floor

    Boston, MA 02116

    (617) 937-2300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated Filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Post-Effective Amendment No. 1 (the “Amendment”), which relates to the Registration Statement filed on Form S-8, File No. 333-281690 (the “Original Registration Statement”) filed with the Securities and Exchange Commission on August 21, 2024 by Tectonic Therapeutic, Inc., a Delaware corporation (the “Registrant”), is being filed solely to file a Consent of Ernst & Young LLP, independent registered public accounting firm of AVROBIO, Inc. attached as Exhibit 23.2 hereto. Except as described herein, this Amendment does not update, amend or modify any other information, statement or disclosure contained in the Original Registration Statement, and all other portions of the Original Registration Statement, as previously filed, remain unchanged. No additional securities are to be registered, and registration fees were paid upon filing of the Original Registration Statement.


    ITEM 8.

    EXHIBITS.

     

    Exhibit
    Number

      

    Description

    4.1+    Fourth Amended and Restated Certificate of Incorporation, as amended through June  20, 2024 (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38537), filed with the SEC on August  14, 2024).
    4.2+    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the SEC on June 25, 2018).
    5.1+    Opinion of Cooley LLP.
    23.1*    Consent of Deloitte & Touche LLP, independent registered public accounting firm of Tectonic Therapeutic, Inc.
    23.2*    Consent of Ernst & Young LLP, independent registered public accounting firm of AVROBIO, Inc.
    23.3+    Consent of Cooley LLP. Reference is made to Exhibit 5.1.
    24.1+    Power of Attorney (included on signature page to the Original Registration Statement).
    99.1+    Tectonic Therapeutic, Inc. 2019 Equity Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.42 to the Registrant’s Registration Statement on Form S-4, filed with the SEC on February 14, 2024).
    99.2+    Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the SEC on June 20, 2024).
    99.3+    Forms of Option Grant Notice, Option Agreement and Notice of Exercise under Tectonic Therapeutic, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the SEC on June 20, 2024).
    99.4+    Tectonic Therapeutic, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Current Report on Form 8-K (File No. 001-38537), filed with the SEC on June 20, 2024).
    107+    Filing Fee Table.

     

    *

    Filed herewith

    +

    Previously filed with the Original Registration Statement.

     

    1


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on August 27, 2024.

     

    TECTONIC THERAPEUTIC, INC.
    By    /s/ Daniel Lochner
      Daniel Lochner
      Chief Financial Officer

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    *

    Alise Reicin

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      August 27, 2024

    /s/ Daniel Lochner

    Daniel Lochner

      

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

      August 27, 2024

    *

    Terrance McGuire

      

    Director

      August 27, 2024

    *

    Stefan Vitorovic

      

    Director

      August 27, 2024

    *

    Timothy A. Springer

      

    Director

      August 27, 2024

    *

    Praveen Tipirneni

      

    Director

      August 27, 2024

    *

    Phillip B. Donenberg

      

    Director

      August 27, 2024

     

    *By:   /s/ Daniel Lochner
      Daniel Lochner
      Attorney-in-Fact

     

    2

    Get the next $TECX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TECX

    DatePrice TargetRatingAnalyst
    10/20/2025$101.00Overweight
    Wells Fargo
    9/3/2025$80.00Outperform
    Oppenheimer
    7/21/2025$64.00Buy
    Truist
    6/11/2025$76.00Outperform
    Raymond James
    4/21/2025$51.00Outperform
    Mizuho
    11/20/2024$65.00Outperform
    Raymond James
    8/22/2024$55.00Overweight
    Wells Fargo
    6/26/2024Overweight
    Piper Sandler
    More analyst ratings

    $TECX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Lochner Daniel bought $129,660 worth of shares (6,000 units at $21.61), increasing direct ownership by 23% to 32,044 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/11/26 5:32:12 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    4/11/25 6:12:08 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    4/9/25 5:38:10 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Lochner Daniel bought $129,660 worth of shares (6,000 units at $21.61), increasing direct ownership by 23% to 32,044 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/11/26 5:32:12 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Business Officer Schwabish Marc covered exercise/tax liability with 1,619 shares, decreasing direct ownership by 7% to 21,314 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/10/26 4:10:40 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Ruddy Marcella K. covered exercise/tax liability with 2,064 shares, decreasing direct ownership by 4% to 53,247 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/10/26 4:09:21 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Tectonic Therapeutic Inc.

    SCHEDULE 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    11/14/25 4:17:57 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Tectonic Therapeutic Inc.

    10-Q - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    11/6/25 4:28:50 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    11/6/25 4:15:50 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

    WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), announced that it will host a virtual key opinion leader (KOL) event and TX2100 discussion on Tuesday, February 24, 2026 from 11:00 a.m. to 12:30 p.m. ET. The event will feature Hanny Al-Samkari, MD (Massachusetts General Hospital, Harvard Medical School), who will join company management. During the event, the management team will review the target, mechanistic rationale, and preclinical evidence sup

    2/11/26 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic to Participate in December Investor Conferences

    WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in December 2025. Piper Sandler 37th Annual Healthcare Conference Date:Time:Location:Format:Presenters:Webcast:December 2, 20253:30 PM ESTNew York, NYFireside ChatAlise Reicin, MD, President and Chief Executive OfficerLink Evercore 8th Annual Healthcare Conference Date:Location:Format:December 3,

    12/1/25 8:00:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights

    Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")Expect to initiate TX2100 Phase 1 clinical trial in healthy volunteers in Q1'2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia ("HHT")TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45's safety and hemodynamic effects in patients with Pulmonary Hypertension associated with Interstitial Lung Disease ("PH-ILD", Group 3 PH) to expand the therapeutic breadth of TX45Ongoing TX45 APEX Phase 2 clinic

    11/6/25 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Tectonic Therapeutic with a new price target

    Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $101.00

    10/20/25 8:03:48 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Tectonic Therapeutic with a new price target

    Oppenheimer initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $80.00

    9/3/25 8:39:51 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Tectonic Therapeutic with a new price target

    Truist initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $64.00

    7/21/25 8:39:42 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Financials

    Live finance-specific insights

    View All

    Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

    TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

    1/30/25 6:30:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

    Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

    11/7/24 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

    TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

    8/14/24 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tectonic Therapeutic Inc.

    SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    11/14/24 4:05:11 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    10/28/24 6:08:43 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    10/24/24 5:12:09 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care